GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ANI Pharmaceuticals Inc (NAS:ANIP) » Definitions » Cyclically Adjusted FCF per Share

ANI Pharmaceuticals (ANI Pharmaceuticals) Cyclically Adjusted FCF per Share : $-2.19 (As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is ANI Pharmaceuticals Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

ANI Pharmaceuticals's adjusted free cash flow per share for the three months ended in Dec. 2023 was $2.070. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-2.19 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 22.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 26.40% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 18.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of ANI Pharmaceuticals was 31.60% per year. The lowest was 0.50% per year. And the median was 13.60% per year.

As of today (2024-04-29), ANI Pharmaceuticals's current stock price is $65.36. ANI Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $-2.19. ANI Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


ANI Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

The historical data trend for ANI Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANI Pharmaceuticals Cyclically Adjusted FCF per Share Chart

ANI Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.84 -4.76 -2.97 -2.49 -2.19

ANI Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.49 -2.28 -2.60 -2.45 -2.19

Competitive Comparison of ANI Pharmaceuticals's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ANI Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ANI Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



ANI Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ANI Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=2.07/129.4194*129.4194
=2.070

Current CPI (Dec. 2023) = 129.4194.

ANI Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.746 99.695 -0.968
201406 0.151 100.560 0.194
201409 -1.625 100.428 -2.094
201412 0.895 99.070 1.169
201503 -0.302 99.621 -0.392
201506 0.087 100.684 0.112
201509 -1.430 100.392 -1.843
201512 0.311 99.792 0.403
201603 -6.492 100.470 -8.363
201606 -4.999 101.688 -6.362
201609 0.000 101.861 0.000
201612 0.919 101.863 1.168
201703 -3.996 102.862 -5.028
201706 -0.197 103.349 -0.247
201709 1.251 104.136 1.555
201712 -2.967 104.011 -3.692
201803 1.764 105.290 2.168
201806 0.198 106.317 0.241
201809 0.589 106.507 0.716
201812 2.225 105.998 2.717
201903 -0.507 107.251 -0.612
201906 0.064 108.070 0.077
201909 1.643 108.329 1.963
201912 0.286 108.420 0.341
202003 -4.691 108.902 -5.575
202006 1.507 108.767 1.793
202009 -0.618 109.815 -0.728
202012 -0.652 109.897 -0.768
202103 1.659 111.754 1.921
202106 -1.796 114.631 -2.028
202109 -0.494 115.734 -0.552
202112 -0.885 117.630 -0.974
202203 -1.309 121.301 -1.397
202206 -0.787 125.017 -0.815
202209 -0.380 125.227 -0.393
202212 -0.462 125.222 -0.477
202303 1.154 127.348 1.173
202306 0.773 128.729 0.777
202309 1.444 129.860 1.439
202312 2.070 129.419 2.070

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


ANI Pharmaceuticals  (NAS:ANIP) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


ANI Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of ANI Pharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ANI Pharmaceuticals (ANI Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
210 Main Street West, Baudette, MN, USA, 56623
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Executives
Muthusamy Shanmugam director, officer: HEAD OF R&D, COO-NOVITIUM OPS C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Meredith Cook officer: SR. VP, GENERAL COUNSEL & SEC. C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Krista Davis officer: SVP, CHIEF HR OFFICER C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Christopher Mutz officer: HEAD OF RARE DISEASE C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Chad Gassert officer: SVP - CORP. DEV. & STRATEGY C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Ori Gutwerg officer: SVP, GENERICS C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
James G. Marken officer: Vice President, Operations 210 MAIN STREET WEST, C/O BIOSANTE PHARMACEUTICALS, INC., BAUDETTE MN 56623
Matthew J Leonard director 7 CUSTOM HOUSE STREET, PORTLAND ME 04101
Meridian Venture Partners Ii Lp 10 percent owner
Nikhil Lalwani director, officer: PRESIDENT & CEO C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623
Antonio R Pera director C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623
Stephen P. Carey officer: Vice President and CFO C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Renee P Tannenbaum director 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Jeanne Thoma director C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780

ANI Pharmaceuticals (ANI Pharmaceuticals) Headlines